DRIVE study validates diagnostic performance of Cxbladder Triage Plus
Leading industry platform Urology Times reviews the DRIVE study, now published in Urologic Oncology. DRIVE provides clinical validation for our next generation Cxbladder test Triage Plus. Cxbladder Triage Plus employs a novel combination of mRNA and RNA biomarkers to extend best in class performance, enhancing the risk stratification of patients presenting with hematuria.
Cxbladder for Hematuria Evaluation and Bladder Cancer Surveillance
Pacific Edge Chief Medical Officer, Dr. Aboushwareb leads an introductory webinar to urological teams in Asia.
Cxbladder is a suite of non-invasive genomic urine test optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. In his talk, Dr. Aboushwareb discussed the challenges clinical teams face and spoke to the utility of the Cxbladder suite, supported with recent data.
- Enhance risk stratification and de-intensify the evaluation of hematuria.
- Resolve atypical cytology and equivocal cystosocopy
- Reduce the burden of NMIBC surveillance cystoscopy
- Improve patient comfort, compliance and management
The Utility of Cxbladder Triage in Microhematuria Evaluation
Pacific Edge Senior Medical Director Dr. Jay Jhaveri hosts an expert panel discussion with Dr. Evan Goldfischer, Dr. Kristen Scarpato, Dr. Ron Loo, and Dr. Zachary Klaassen focused on the use of Cxbladder Triage, a urine-based tumor marker (UBTM) test, in the evaluation of patients presenting with microhematuria. Topics covered include:
- Incorporating the new AUA/SUFU Microhematuria Guideline* in practice
- Practical learnings from a recent Kaiser Permanente study of over 3,300 patients**
- Challenges in incorporating UBTMs in practice – and how to overcome them
- Leveraging UBTMs to improve practice efficiency
- UBTMs in the context of recent CMS guidance regarding billing and coding
The Utility of Cxbladder Triage for Microhematuria Evaluation: Short Clips
Implementing the New AUA/SUFU Microhematuria Guideline in Practice
Prioritizing High Yield Visits
Optimizing Practice Workflow. Prioritizing Those Who Require Care
Revenue Cycle Management
Featured Videos
The Role of Urine-based Biomarkers in Microhematuria Evaluation
In a recent interview with Urology Times, Dr. John Sfakianos discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA randomized controlled trial.
The 2025 AUA/SUFU Microhematuria Guideline
Ground Rounds in Urology's Diane Newman hosts Dr. Jason Hafron, Chief Medical Officer at Michigan Institute of Urology. Dr Hafron reviews the 2025 AUA/SUFU amendment to the Microhematuria Guideline, detailing refinements in risk stratification, diagnostic approach, and integrating urinary biomarkers.
Industry Perspective: Cxbladder Triage Inclusion in the 2025 AUA/SUFU Microhematuria Guideline
Host Diane Newman and Pacific Edge Senior Medical Director Dr. Jay Jhaveri discuss key changes incorporated into the 2025 AUA/SUFU Microhematuria Guideline and the implications for clinical practice. The updated Guideline emphasizes refined risk stratification and suggests a more efficient approach to managing intermediate risk patients leveraging Cxbladder Triage.
Featured Survey: Surveillance patients show strong interest in non-invasive test options
In December 2023, 1,507 patients being monitored for recurrent NMIBC were questioned using the Bladder Cancer Advocacy Network’s (BCAN’s) Patient Survey Network.
Surveyed patients were receptive to urine-based testing
- 80% of patients said having a urine-based surveillance test alternative was moderately to extremely important.
- Surveyed patients were then presented with introductory information on Cxbladder Monitor and asked if they would be willing to use the test to reduce the frequency of surveillance cystoscopy - 90% were interested and wanted to learn more.
Featured Videos
Platform Reduces Unnecessary Cystoscopies for Hematuria
Dr. Zachary Klaassen interviews Dr. John Sfakianos about implementing the Cxbladder platform for microhematuria risk stratification and bladder cancer surveillance. Dr. Sfakianos discusses how high-quality biomarkers address the longstanding need to avoid over-diagnosing patients with microhematuria, where historically everyone received cystoscopy despite most having no significant findings.
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines
Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA/SUFU Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now included in the Guideline*.
Real-World Implementation of Biomarkers for Microhematuria Workup
Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join Dr. Zachary Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a published study of over 3,300 patients.
Additional Video Webinars and Articles
- SESAUA 2025 Symposium: Cxbladder Triage - Risk Stratification for Patients with Microhematuria. Mar, 2025. Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Wellstar MCG, Georgia Cancer Center, Augusta, GA.
- Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial. UroToday, Jun, 2024. Yair Lotan, MD, Urologist, UT Southwestern Medical Center, Tamer Aboushwareb, MD, Chief Medical Officer, Pacific Edge.
- The Promise, Potential, and Practicality of Cxbladder in Modern Urologic Oncology. UroToday, Nov, 2023. Mark Tyson MD, Zach Klassen MD.
- Use of the Cxbladder Monitor Genomic Urine Test for Surveillance of Patients with Non-Muscle-Invasive Bladder Cancer. Ground Rounds in Urology, Mar, 2023. Daniel Shoskes, MD; John P. Sfakianos, MD; and Sima P. Porten, MD, MPH.
- From Science to Clinical Utility: Cxbladder Monitor - Bladder Cancer Surveillance for Patients with Urothelial Carcinoma. UroToday, Dec, 2022. Tamer Aboushwareb, MD, PhD, Vice President of Medical Affairs, Pacific Edge Ltd. Joshua Meeks, MD, PhD, Edward M. Schaeffer, Professor of Urology, Associate Professor of Urology and Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL. Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
- From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria. UroToday, Nov, 2022. Tamer Aboushwareb, MD, Joshua Meeks, MD, Neal D. Shore, MD.
- From Science to Clinical Utility: The Role of Cxbladder in Bladder Cancer Diagnosis & Management. Grand Rounds Urology, Oct 2022. Tamer Aboushwareb, MD, PhD, Vice President of Medical Affairs, Pacific Edge, Ltd.
- Bladder Cancer Matters Podcast: How COVID Changed How Bladder Cancer Doctors and Patients Interact. Sept, 2022. Sima Porten, MD (UCSF) and Bladder Cancer Matters Host, Rick Bangs (BCAN) discuss how COVID has changed the way bladder cancer doctors and patients interact.
- BCAN Think Tank: Bladder Cancer Screening. Aug, 2022. Prof Yair Lotan (UT Southwestern Medical Center at Dallas) and Prof Joshua Meeks (Northwestern Medicine, Chicago) present at BCAN's Think Tank 2022 in Denver, Colorado. Dr Yair Lotan's presentation begins 24:42, Dr Joshua Meeks' presentation begins 42:45.
- Advances in Bladder Cancer Diagnostics: Introducing a clinical pathway that reduces the need for flexible cystoscopy for hematuria. July, 2022. Peter Davidson, MD presents at Urofair 2022 in Singapore.
- Grand Rounds in Urology: Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer. May, 2021. Sia Daneshmand, MD (Keck School of Medicine, USC), leads discussion with Sima Porten, MD (UCSF), and Anne Schuckman, MD (USC).
- UroToday: Alternative Strategies to Deliver Urology Care/ Bladder Cancer Investigation during COVID-19 and Beyond. Apr, 2020. Neal Shore, MD (Medical Director, Carolina Urologic Research Center) leads discussion with Sima Porten, MD (UCSF), and Thomas Nifong, MD, (Pacific Edge Diagnostics USA).
- Urology Times: How the COVID-19 Pandemic Impacts Practice Management & Telemedicine. Apr, 2020. Urology Times' Jonathan Rubenstein, MD, leads discussion with John Gore, MD (University of Washington), Aaron Spitz, MD (University of California), and Eugene Rhee, MD (Kaiser Permanente). Discussion of telemedicine and urinary biomarkers begins 50.52.
- BCAN Patient Webinar: What You Should Know About Covid-19 and Bladder Cancer. Apr, 2020. Stephanie Chisolm, Director of Education & Research at the Bladder Cancer Advocacy Network (BCAN) leads discussion with Sia Daneshmand, MD (Keck School of Medicine, USC); Professor Sandy Srinivas (Stanford Medicine); and Alec Koo, MD. Cxbladder specific discussion begins 28:12 (part 1), 46:50 (part 2).
- UroToday: Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Nov, 2019. Neal Shore, MD, and Badrinath Konety, MD.
- UroToday Journal Club: The Evaluation of Cxbladder and Adjudication of Atypical Cytology. Oct, 2019. Sia Daneshmand, MD.
- Urine Biomarkers for the Detection of Urothelial Carcinoma. New York, July 2019. Sia Daneshmand, MD, University of Southern California presents at Life Science Ventures KOL Event in New York on urinary biomarkers in bladder cancer.
- Cxbladder for Hematuria Assessment and Follow-up of Low-grade Bladder Cancer. Urofair Singapore, Apr 2019. Madhusudan Koya, Clinical Director, Waitemata DHB discusses new data on Cxbladder adoption in Canterbury and Waitemata.
- Urine Biomarkers for the Detection of Urothelial Carcinoma. Urofair Singapore, Apr 2019. Sia Daneshmand, MD, University of Southern California presents to SUA at Urofair on urinary biomarkers in bladder cancer.
- Urinary Markers in Bladder Cancer. Grand Rounds in Urology (Feb 2018). Peter Black, MD, discusses the benefits and limitations of the currently FDA approved and commercially available urinary biomarkers for bladder cancer.
- Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder. Grand Rounds in Urology (Dec, 2017). Sia Daneshmand, MD, University of Southern California gives an overview of hematuria and some of the new urinary molecular marker tests in bladder cancer.
- The Development and Clinical Validation of a High Sensitivity Urine biomarker test for the Determination of Recurrence in Urothelial Carcinoma Patients. Plenary at the American Urological Association (AUA) Annual Meeting, San Diego, May 2016.